United Therapeutics UTHR Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| Adcirca | $26.9M-10.3% | $30M+11.5% | $26.9M+11.2% | $24.2M+3.4% | $23.4M-1.7% | |
| Nebulized Tyvaso | $549.1M-6.2% | $585.7M-2.8% | $602.7M-2.8% | $620.1M+2.4% | $605.6M+3.2% | |
| Orenitram | $511.8M+3.0% | $496.9M+2.8% | $483.5M+3.8% | $465.6M+3.7% | $448.8M+3.3% | |
| Remodulin | $515.2M-2.2% | $526.8M-1.2% | $533.3M-0.4% | $535.7M-2.3% | $548.3M+1.9% | |
| Tyvaso DPI | $1.32B+2.2% | $1.29B+5.3% | $1.23B+5.3% | $1.17B+5.1% | $1.11B+7.3% | |
| Unituxin | $222.2M-2.0% | $226.8M-2.2% | $232M-5.4% | $245.2M+2.8% | $238.5M-0.1% | |
| Total revenues by Geography | ||||||
| ROW | $138.2M-5.1% | $145.7M+5.2% | $138.5M-4.7% | $145.4M-0.6% | $146.3M+6.2% | |
| U.S. | $3.03B-0.2% | $3.04B+1.6% | $2.99B+2.0% | $2.93B+3.0% | $2.85B+3.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does United Therapeutics break its business down?
- United Therapeutics (UTHR) reports total revenues by product across 6 parts — Adcirca, Nebulized Tyvaso, Orenitram, Remodulin and Tyvaso DPI. Each is extracted from the segment footnotes and tracked over time.
- Where does United Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in United Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
